COVID19 Clinical Trial
— PROVID-19Official title:
Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress
Verified date | December 2022 |
Source | Centre Hospitalier Régional d'Orléans |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The SARS-Cov2 viral pandemic is responsible for a new infectious disease called COVID-19 (CoronaVIrus Disease), is a major health problem. Respiratory complications occur in 15 to 40%, the most serious is acute respiratory distress syndrome (ARDS). The management of COVID-19 is essentially symptomatic with respiratory oxygen supplementation in mild forms to invasive mechanical ventilation in the most severe forms. Prone position (PP) reduced mortality in patients with ARDS in intensive care. Ding et al showed that PP and high flow oxygenation reduced the intubation in patients with moderate to severe ARDS. The investigators hypothesize that the use of PP in spontaneously ventilation patients under oxygen standard could decrease incidence of intubation or non-invasive ventilation or death compared to conventional positioning management in medical departments.
Status | Completed |
Enrollment | 268 |
Est. completion date | January 13, 2022 |
Est. primary completion date | January 13, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Patients aged from 18 to 85 years old - With COVID-19 documentation - Undergoing oxygen therapy (nasal cannula, medium or high concentration mask or high flow nasal oxygen therapy) - Able to move to PP by him/herself or with minimal assistance - Written consent - Hospitalized in COVID medical department for less than 72 hours Exclusion Criteria: - Pregnant (positive pregnancy test during screening) or breastfeeding women - Patient on long-term oxygen therapy or Continuous Positive Airway Pressure (CPAP) or Non-Invasive Ventilation (NIV) at home - Chronic Obstructive Pulmonary Disease (COPD) Patient stage 3 or 4 - Patient with known chronic diffuse interstitial lung disease - Patient with neuromuscular pathology - Contraindication to the PP (recent thoracic trauma, pneumothorax, orthopaedic fracture preventing mobilization, ...) - Deep vein thrombosis of the lower limbs or pulmonary embolism with effective anticoagulation for less than 48 hours - Hemodynamic instability (MAP < 65 mm Hg) persisting for more than 1 hour - Respiratory rate greater than 40 cycles per minute - Excessive use of accessory respiratory muscles (as judged by the clinician) - Indication for curative NIV (acute pulmonary edema or acute hypercapnic respiratory failure) - Intestinal Occlusive Syndrome - Patient unable to protect upper airway - Inability to understand French or to follow instructions for the prone position. - Person under guardianship - Protected Majors - Not affiliated to French social security - Decision not to forgo life sustaining therapy - Patient discharged from an intensive care unit and has been treated by invasive or non-invasive mechanical ventilation at 2 pressure levels during the resuscitation stay. |
Country | Name | City | State |
---|---|---|---|
France | CH de Blois | Blois | |
France | CH de DAX | Dax | |
France | CHD de VENDEE | La Roche sur Yon | |
France | CH de LA ROCHELLE | La Rochelle | |
France | CH Le Mans | Le Mans | |
France | CH Mont de MArsan | Mont-de-Marsan | |
France | CHR d'Orleans - Service Maladies Infectieuses | Orléans | |
France | CHR d'Orléans - Service Pneumologie | Orléans | |
France | Hopital Européen Georges Pompidou | Paris | |
France | Hopital Lariboisiere | Paris | |
France | Hopital Lariboisiere - Medecine Interne | Paris | |
France | HOPITAL LARIBOISIERE - Service diabétologie, endocrinologie, nutrition | Paris | |
France | CH de PERPIGNAN - Service Maladies infectieuses | Perpignan | |
France | Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau | Quimper | |
France | CHRU de Tours - Service Médecine interne et immunologie Clinique | Tours | |
France | CHRU DE TOURS - Service Médecine interne et maladies infectieuses | Tours | |
France | CHRU de Tours - Service Pneumologie | Tours | |
France | CH Bretagne Atlantique | Vannes | |
Monaco | centre Hospitalier Princesse Grace | Monaco |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Régional d'Orléans |
France, Monaco,
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;: — View Citation
Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA. 2020 Apr 21;323(15):1499-1500. doi: 10.1001/jama.2020.3633. No abstract available. — View Citation
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum In: JAMA Intern Med. 2020 Jul 1;180(7):1031. — View Citation
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum In: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups. | To show that PP in spontaneously ventilation patients could reduce the risk of acquiring the following event (composite endpoint):
Endotracheal intubation Or non-invasive ventilation (NIV) with two pressure levels And/or death |
Day 28 | |
Secondary | Duration in days for the change of 2 points on the WHO ordinal scale | Show that the use of prone position improves the WHO ordinal scale score by 2 points faster (after randomization) | Day 28 | |
Secondary | Rate (%) of intubation and invasive ventilation in the 2 randomization groups. | Show that prone position with spontaneous ventilation reduces the need for endotracheal intubation and invasive mechanical ventilation | Day 28 | |
Secondary | Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups | Show that prone position with spontaneous ventilation reduces the use of non-invasive ventilation at two pressure levels | Day 28 | |
Secondary | Duration of oxygen therapy in the 2 randomization groups. | Show that prone position in spontaneous ventilation reduces the time under oxygen therapy. | Day 28 | |
Secondary | Duration of hospitalization in the 2 randomization groups. | Show that prone position reduces the length of hospitalization. | Day 28 | |
Secondary | Hospital mortality and mortality at D28 in the 2 randomization groups | Compare the hospital mortality of the 2 groups | Day 28 | |
Secondary | Rate (%) of need for transfer to intensive care unit | Compare the incidence of the need for resuscitation transfer between the two groups. | Day 28 | |
Secondary | Rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days. | Compare the impact of the use of non-invasive ventilation and intubation on the entire hospital stay when the hospital stay is longer than 28 days between the two groups. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |